EMERGENT-3 was a phase 3, multicenter, randomized clinical trial used to confirm the results reported in EMERGENT-1 and EMERGENT-2. A total of 256 individuals were included with a mean age of 43.1 years, 74.6% were male, and 60.9% were Black or African American. Patients received xanomeline and trospium chloride (maximum dose of xanomeline 125 mg/trospium 30 mg) or the placebo for 5 weeks. The primary end point was change from baseline to week 5 PANSS total score, with secondary outcomes including change from baseline to week 5 PANSS positive subscale score, PANSS negative subscale score, PANSS Marder negative factor score, Clinical Global Impression-Severity score, and proportion of individuals with at least a 30% reduction in PANSS total score.2
In EMERGENT-3, xanomeline and trospium chloride demonstrated clinically meaningful and statistically significant 8.4-point reduction in Positive and Negative Syndrome Scale (PANSS) compared with the placebo at 5 weeks. The drug also demonstrated a reduction in both positive and negative symptoms, measured by PANSS positive, PANSS negative, and PANSS negative Marder factor subscales, which were the secondary outcomes of the study. There was a 3.5-point reduction in PANSS positive score.3
About The Trial
Trial Name: A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)
ClinicalTrials.gov ID: NCT04738123
Sponsor: Karuna Therapeutics
Study Completion Date: December 2022
Investigators noted that the prespecified PANSS negative subscale score did not meet statistically significance at week 5, but the least-square mean changed form baseline in PANSS negative subscore and PANSS Marder negative factor score did achieve statistical significance at week 4.2
For safety, investigators found that the drug was generally well tolerated, with the overall discontinuation rate of 37% compared with 29% with the placebo. The most common treatment emergent adverse events (TEAEs) were constipation, diarrhea, dyspepsia, headache, hypertension, insomnia, and nausea. TEAE occurred in 70% in the drug arm and 50% in the placebo arm, with discontinuation rates due to TEAS being 6% and 5%, respectively.3
REFERENCES
1. U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults. News release. Bristol Myers Squibb. September 26, 2024. Accessed September 27, 2024. https://news.bms.com/news/corporate-financial/2024/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-COBENFY-xanomeline-and-trospium-chloride-a-First-In-Class-Muscarinic-Agonist-for-the-Treatment-of-Schizophrenia-in-Adults/default.aspx
2. Kaul I, Sawchak S, Walling DP, et al. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2024;81(8):749–756. doi:10.1001/jamapsychiatry.2024.0785
3. Gallagher A. Schizophrenia Treatment KarXT Meets Primary Endpoint in Phase 3 Trial. Pharmacy Times. March 27, 2023. Accessed September 27, 2024. https://www.pharmacytimes.com/view/schizophrenia-treatment-karxt-meets-primary-endpoint-in-phase-3-trial